about
sameAs
Pharmacological interventions for cognitive decline in people with Down syndromeNeurological phenotypes for Down syndrome across the life spanCharacteristics of adults with down syndrome: prevalence of age-related conditionsAge-related neurodegeneration and memory loss in down syndrome.Aging and down syndromeA Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Rivastigmine for dementia in people with Down syndrome
@ast
Rivastigmine for dementia in people with Down syndrome
@en
Rivastigmine for dementia in people with Down syndrome
@en-gb
Rivastigmine for dementia in people with Down syndrome
@nl
type
label
Rivastigmine for dementia in people with Down syndrome
@ast
Rivastigmine for dementia in people with Down syndrome
@en
Rivastigmine for dementia in people with Down syndrome
@en-gb
Rivastigmine for dementia in people with Down syndrome
@nl
prefLabel
Rivastigmine for dementia in people with Down syndrome
@ast
Rivastigmine for dementia in people with Down syndrome
@en
Rivastigmine for dementia in people with Down syndrome
@en-gb
Rivastigmine for dementia in people with Down syndrome
@nl
P2860
P1476
Rivastigmine for dementia in people with Down syndrome
@en
P2093
Monica Mohan
Peter K Carpenter
P2860
P304
P356
10.1002/14651858.CD007658
P407
P577
2009-01-21T00:00:00Z